Skip to main content
. 2021 Sep 2;10(9):1410. doi: 10.3390/antiox10091410

Figure 2.

Figure 2

Leukemia cell viabilities following EANT treatment. (A) MTS assay at 24, 48, and 72 h. (B) Pretreatment impact of NAC and ZVAD on cell viability. Cells (HL-60, K-562, and MOLT-4) were pretreated with NAC (5 mM, 1 h), ZVAD (100 μM, 2 h), or instead post-treated with EANT (0 and 4 μg/mL for 24 h). The 0 μg/mL solution contained no EANT but contained 0.1% DMSO. (C) MTS assay at 24, 48, and 72 h for the main isolated compound plumbagin in EANT. Data, mean ± SD (n = 3). Data showing different alphabets at the top revealed a significant difference (p < 0.0001 for multiple comparisons). In the example of HL-60 cells (Figure 2B), the EANT 0, NAC/EANT 0, ZVAD/EANT 0, and NAC/EANT 0 show “a”, indicating nonsignificant differences between each other because they overlap with the same lower-case letters. Similarly, the NAC/EANT 0, ZVAD/EANT 4, and EANT 4 showing “a, b, and c” indicate significant differences among each other.